Continuous Glucose Monitoring in Cystic Fibrosis Patients According to the Glucose Tolerance

Abstract

Cystic fibrosis (CF) is associated with a long preclinical state of abnormal glucose tolerance. The aim of this study was (i) to evaluate the profile of glucose tolerance in young adults with CF and (ii) to compare these results with those obtained by a continuous subcutaneous glucose monitoring (CGMS). CF subjects with fasting glycemia inferior to 126 mg/dl were included in the study. An oral glucose tolerance test (OGTT) identified the subjects either with a normal glucose tolerance (NGT), or impaired glucose tolerance (IGT), or diabetes. CGMS (Medtronic) was performed during 3 days to analyze mean glucose level, high glucose excursions, and glucose area under the curve (AUC). Forty-nine patients were included in the study. NGT (n=22), IGT (n=17), and diabetes groups (n=10) were comparable except with regard to age and BMI (p<0.001). HbA1c values in diabetes group were significantly higher (p<0.001) than in NGT and IGT groups. CGMS revealed peaks of glucose values superior to 200 mg/dl at least once after a meal in 8 patients (36%) with NGT, in 9 patients (52%) with IGT, and in all patients with diabetes (p<0.01). Mean CGMS glucose and glucose AUC values increased in patients with diabetes compared to patients with NGT and IGT (p<0.05). Peak of CGMS glucose reached 182±60 mg/dl in NGT group despite the normal glucose profile at OGTT. In conclusion, CGMS revealed pathological glucose excursions not only in patients with impaired glucose tolerance at OGTT but also in patients with a normal glycemic profile. CGMS could be a useful tool for the early detection of hyperglycemia in patients with CF.

Key words

cystic fibrosis - continuous glucose monitoring - cystic fibrosis related-diabetes

References

• 1 Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis.  Eur J Pediatr. 1992;  151 684-687
• 2 Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes.  J Cyst Fibros. 2004;  3 209-222
• 3 Costa M, Potvin S, Berthiaume Y, Gauthier L, Jeanneret A, Lavoie A, Levesque R, Chiasson JL, Rabasa-Lhoret R. Diabetes : a major co-morbidity of cystic fibrosis.  Diabetes Metab. 2005;  31 221-223
• 4 Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell II, Chesrown SE, Duchow C, Fink RJ, Fitzsimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Zipf WB. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus. A consensus conference report.  Diabetes Research and Clinical Practice. 1999;  45 61-73
• 5 Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis.  J Pediatr. 1991;  118 715-723
• 6 Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis.  J Pediatr. 1998;  133 10-17
• 7 Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction.  Diabet Med. 2002;  19 221-226
• 8 Tofé S, Moreno JC, Maiz L, Alonso M, Escobar H, Barrio R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.  European J Endocrinol. 2005;  152 241-247
• 9 Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment.  Arch Dis Child. 2002;  87 430-431
• 10 Kessler L, Passemard R, Oberholzer J, Benhamou PY, Bucher P, Toso C, Meyer P, Penfornis A, Badet L, Wolf P, Colin C, Morel P, Pinget M. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation. Interest of continuous glucose monitoring.  Diabetes Care. 2002;  25 2256-2262
• 11 Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH. Performance evaluation of the MiniMed continuous glucose monitoring system during home patient use.  Diabetes Technol Ther. 2000;  2 49-56
• 12 Dobson L, Sheldon CD, Hattersley AT. Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis.  Diabetes Care. 2003;  26 1940-1941
• 13 Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, Philips BJ, Hodson ME, Geddes DM, Baker EH. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis.  J Cyst Fibros. 2007;  6 101-109
• 14 Jefferies C, Solomon M, Perlman K, Sweezey N, Daneman D. Continuous glucose monitoring in adolescents with cystic fibrosis.  J Pediatr. 2005;  147 396-398
• 15 Mastrototaro J. The Minimed continuous glucose monitoring system (CGMS).  J Pediatric Endocrinol Metab. 1999;  12 751-758
• 16 Rebrin K, Steil GM, Antwerp WP Van. Subcutaneous glucose predicts plasma glucose independent of insulin: implication for continuous monitoring.  Am J Physiol. 1999;  277 561-571
• 17 Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes.  J Pediatr. 2005;  146 681-687
• 18 Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Conventional measures underestimate glycaemia in cystic fibrosis patients.  Diabet Med. 2004;  21 691-696
• 19 Rafii M, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, Tullis E, Pencharz PB. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis.  Am J Clin Nutr. 2005;  81 421-426
• 20 Wagener JS, MacNeill GC, Taussig LM, Corrigan JJ, Lemen R. Ferrokinetic and hematologic studies in cystic fibrosis patients.  Am J Pediatr Hematol Oncol. 1983;  5 143-160
• 21 Brennan AL, Gyi KM, Wood DM, Hodson ME, Geddes DM, Baker EH. Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis.  Journal of Cystic Fibrosis. 2006;  5 27-31
• 22 Pistrosch F, Koehler C, Wildbrett J, Hanefelg M. Relationship between diurnal glucose levels and HbA1c in type 2 diabetes.  Horm Metab Res. 2006;  38 455-459
• 23 Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance.  J Endocrinol Invest. 2006;  29 1-4
• 24 Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N. et al . Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy.  Acta Paediatr. 2001;  90 860-867

1 On behalf of CRCM-Alsace

Correspondence